OBJECTIVES: The study aims to survey prices of biological medicines before and after the entry of the first biosimilar in a European country and examine which factors influence the development of prices. *** METHODS: Pharmaceutical Price Information service located at the Austrian National Public Health Institute provided price information for pharmaceutical specialities of nine different biological active ingredients (adalimumab, enoxaparin, etanercept,infliximab, insulin glargin, insulin lispro, pegfilgrastim, rituximab, trastuzumab). Data on the list prices has been collected 6 months prior the first biosimilar entered the market of any European country until June 2019. The prices have been indexed to the respective national price level at the time of the biosimilar entry in order to facilitate cross-country comparisons over the period. *** RESULTS: As of June 2019, 41 biosimilar are available which distribute among 17 pharmaceutical specialities (defined as same active ingredient, same strength and same pharmaceutical form). The largest number of biosimilars has been observed for adalimumab (7), while only one biosimilar is available or insulin lispro. Price developments for biosimilars show more dynamics than those of originator medicines, on average the median price level of biosimilars among European countries is 20% lower than those of the originator medicines. The median price level of originator products is lowest for etanercept, while for Biosimilars it is adalimumab. *** DISCUSSION: The price level of biological medicines decrease after the entry of biosimilars on the market, but the magnitude of these reductions varies between the active ingredients, pharmaceutical specialities and countries. The reasons for the observed variation are: (1) Price link: Several countries have introduced for biosimilar a so-called price link, which is the practice of setting the price at a certain percentage lower than the originator/reference medicine price. In some countries this policy also include provisions on lowering prices for originator which has an impact of price developments. (2) Number of bosimilars: The number of available biosimilars has an impact on price developments for biosimilars but the originator price levels seems to be less affected. While the median price level of adalimumab biosimilar dropped to 63% within one year, the median price level of the adalimumab originator remained almost at the starting point. (3) Point of administration: Some of the biological medicines (e.g. trastuzumab) are administered in a rather specialised environment i.e. hospital, and pricing in this sector may follow different principles than in the outpatient sector. As a result published list prices are not able to capture price dynamics in the inpatient sector.